Project LIPICARE - Combining nanotechnology, gene editing and CAR-T to create a 'one-shot' cure for cancer

LIPICARE是一个由英国基因和癌症治疗领域的顶尖科学家组成的财团构思的一个大胆而雄心勃勃的项目。我们的目标是将纳米技术、细胞疗法和基因编辑的进步结合起来，创造一种一次性治愈癌症的方法。嵌合抗原受体--T细胞(CAR-T)癌症免疫疗法涉及通过基因操作免疫细胞来攻击癌症，代表着一个价值200亿美元的全球市场。批准的CAR-T产品都是体外疗法，涉及在实验室操纵细胞并将其重新引入患者体内的复杂而昂贵的过程。最重要的是，一个挑战阻碍了这项革命性技术的广泛采用，即无法安全有效地将治疗性核酸输送到体内的特定细胞。新城疫19大流行强调表明，脂质纳米颗粒(LNP)mRNA输送平台对人类是安全和有效的。此外，这些LNP-mRNA疫苗的生产成本低至15 GB一剂。下一步是将这些基因传递技术引导到体内的特定细胞。该项目将打破目前的传递障碍，创造T细胞特异性LNP-核酸传递技术，在体内创造CAR-T细胞，从而产生一种具有成本效益的、可获得的癌症治疗方法--LIPICARE项目。

LIPICARE is a bold and ambitious project conceived by a consortium of the UK's leading scientists in the field of gene and cancer therapy. We aim to combine advances in nanotechnology, cell therapy and gene editing to create a one-shot cure for cancer.Chimeric Antigen Receptor -- T cell (CAR-T) cancer immunotherapy involves genetically manipulating immune cells to attack cancers and represents a global market worth 20 billion dollars. Approved CAR-T products are all ex vivo therapies involving the complex and expensive process of manipulating cells in a lab and re-introducing them into a patient. One challenge, above all else, has prevented widespread adoption of this revolutionary technology, namely the inability to deliver therapeutic nucleic acids safely and effectively to the specific cells in the body.The COVID 19 pandemic has emphatically shown the lipid nanoparticle (LNP) mRNA delivery platforms are safe and effective in humans. Moreover, these LNP-mRNA vaccines can be manufactured for as little as £15 a dose. The next step is to guide these gene delivery technologies to specific cells in the body. This project will break down this current delivery barrier by creating T-cell specific LNP-nucleic acid delivery technologies to create CAR-T cells in vivo resulting in a cost-effective, accessible treatment for cancer -- Project LIPICARE.